Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 17;10:2936. doi: 10.3389/fimmu.2019.02936

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Toor, Murshed, Al-Dhaheri, Khawar, Abu Nada and Elkord.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Levels of CD4⁺ and CD4⁺CTLA-4⁺ T cells in CRC patients with different staging and tumor budding. Patients were divided into two groups based on pathologic staging; early stage (Stage I and II) and advanced stage (Stage III and IV). Scatter plots show differences in levels of CD4⁺ and CD4⁺CTLA-4⁺ T cells in PBMC (A), NILs (B), and TILs (C) between CRC patients with early and advanced stages. Patients were also divided into three groups based on degree of tumor budding; low, intermediate and high. Scatter plots show differences in levels of CD4⁺ T cells in PBMC (D), NILs (E), and TILs (F) between CRC patients. ^*P < 0.05.